ANG Boon Thong, Abel

Adjunct Associate Professor
College of Business (Nanyang Business School)

Email: BTAng@ntu.edu.sg

Biography

Mr. Abel Ang is the Group Chief Executive Officer of Advanced MedTech Holdings, a US$200M global player in Urology devices and services. Mr. Ang has a proven track record in the medical device sector. He has served as the Senior Advisor to the CEO of Greatbatch Inc (NYSE: ITGR), providing guidance relative to the commercialization of medical device technologies in the cardiac, neurology, vascular and orthopaedic markets. Before Greatbatch, Mr. Ang was President, Asia/Pacific for Hill-Rom Inc., a US$3B revenue medical devices company (NYSE: HRC) where he was responsible for leading, developing, and implementing the strategy to expand Hill-Rom's presence in the Asia/Pacific markets. He formerly served as the Chief Technology Officer for Hill-Rom for three years. In that role, he had overall responsibility for Hill-Rom's global R & D operations distributed across sites in the U.S., Mexico, France, and Singapore. At Hill-Rom, he also held the positions of Vice-President and General Manager of Hill-Rom's US$420M Global Surfaces and Therapy Business unit, and Vice-President for International Business and Technology Development. He formerly headed the global Medical Technology and Biotechnology industry groups in the Singapore Economic Development Board's (EDB) Biomedical Division.

Mr. Ang sits on the Board of Economic Development Innovations Singapore, a privately-held company headquartered in Singapore. With expertise honed in conceiving and managing townships in India, Vietnam, China, and Indonesia, EDIS's core business is investing, managing, and developing integrated cities globally. Ang also sits on the Board of Accelerate Technologies, which provides access to Singapore's largest intellectual property pool and knowledge generated by over 2,000 researchers at A*STAR's research institutes. Besides, he sits on the Boards of the following operating and investment companies: Dornier MedTech, AMT Pte Ltd, and SonoMotion. He chairs the Board of AWAK Technologies, which is developing a novel diagnosis device. He was formerly on the Board and Nominating Committee of Aslan Pharmaceuticals (NYSE: ASLN).

Mr. Ang is an Adjunct Associate Professor at the Nanyang Business School in Singapore and Waseda University in Japan, where he teaches in their respective MBA programs.

Mr. Ang has a Master of Science in Computational Biology from Rutgers University in New Jersey, which he pursued while on an EDB scholarship. He attended Harvard Business School's Advanced Management Program in 2012.